Microcapsules containing Peppermint essential oil

Dry microcapsules obtained by coacervation containing peppermint essential oil, specifically designed for the protection of the active ingredient in a gastric acid environment where, in the form as it is, it could generate gastric irritation. The microcapsules facilitate the delivery of the active ingredient (peppermint essential oil) to the intestine, thus increasing its therapeutic efficacy [1].

The microcapsules can be added to solid oral formulations - also in association with other active ingredients - such as hard capsules or single-dose, dispersible or buccal sachets, while maintaining unaltered the therapeutic characteristics of the oil.

Thanks to its major components, Menthol and Menton, peppermint essential oil is known for its carminative and cholagogue properties and for its beneficial effects in digestive disorders due to its calcium antagonistic and spasmolytic actions [2], [3]. It is also an excellent antineuralgic and decongestant remedy.

Peppermint essential oil is known to cause irritation if in direct contact with the gastric mucosa. The use of the active ingredient in microcapsules protected by a gastro-resistant gelatine membrane allows the transit of the active ingredient in the gastric tract, reducing direct contact of the oil with the mucosa, thus contributing to the reduction of the typical side effects of the active ingredient as it is.

"[1]. P.P. Shah et al. “A review of medicinal uses and pharmacological effects of Mentha piperita” Natural Product Radiance Vol. 3(4) July/August 2004"

"[2]. Hills J.M., et al. “The mechanism of action of peppermint oil on gastrointestinal smooth muscle” Gastroenterology 101(1991): 55–65"

"[3]. G. Holtmann et al. “Effects of a fixed combination of peppermint oil and caraway oil on symptoms and quality of life in patients suffering from functional dyspepsia”Phytomedicine 10 (2003) · Supplement IV; pp. 56–57"

"[4]. A. Ford et al. “Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis” BMJ 2008;337:a2313"